European Journal of Clinical Pharmacology

, Volume 47, Issue 5, pp 467–468 | Cite as

CNS research in the pharmaceutical industry

A personal view of how innovation could be promoted by clinical pharmacology
  • R. Horowski
Letter to the Editors

Key words

Drug development Pharmaceutical industry CNS research orphan indications clinical pharmacology 


  1. 1.
    Conway J (1993) Cardiovascular research in the pharmaceutical industry: a personal appeal for rationalizing development. Eur J Clin Pharmacol 45: 395–396Google Scholar
  2. 2.
    Dorow R, Horowski R, Paschelke G, Amin M, Braestrup C (1983) Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet II: 98–99Google Scholar
  3. 3.
    Schachter M, Bédard P, Debono AG, Jenner P, Marsden CD, Price P, Parkes JD, Keenan J, Smith B, Rosenthaler J, Horowski R, Dorow R (1980) The role of D1 and D2 receptors. Nature 286: 157–159Google Scholar
  4. 4.
    Horowski R, Sastre-y-Hernandez M (1985) Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res 38: 23–29Google Scholar
  5. 5.
    Meltzer HY (ed) (1987) Psychopharmacology, the third generation of progress. Raven Press, New YorkGoogle Scholar
  6. 6.
    Calne DB (ed) (1994) Neurodegenerative diseases. Saunders, PhiladelphiaGoogle Scholar
  7. 7.
    AMDP and CIPS (eds) (1990) Rating scales for psychiatry, Beltz, WeinheimGoogle Scholar
  8. 8.
    Dirnagel U, Villringer A, Einhäupl KM (eds) (1993) Optical imaging of brain function and metabolism. Adv Exp Med Biol 333, Plenum Press, New YorkGoogle Scholar
  9. 9.
    Mazière B, Mazière M (1990) Where have we got to with neuroreceptor mapping of the human brain? Eur J Nucl Med 16: 817–835Google Scholar
  10. 10.
    Paty DW, Li DKB, UBC MS-MRI Study Group, IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis. II. MRS analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662–667Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • R. Horowski
    • 1
  1. 1.BerlinGermany

Personalised recommendations